Short-Acting Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Apidra, Novolog, Humalog, Novolin, Others), By Application (Type 1 Diabetes, Type 2 Diabetes), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 6.75 billion

CAGR (2024-2029)

4.05%

Fastest Growing Segment

Apidra

Largest Market

North America

Market Size (2029)

USD 8.59 billion

 

Market Overview

Global Short-Acting Insulin Market was valued at USD 6.75. Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.05% through 2029. The Short-Acting Insulin Market is a dynamic and crucial component of the global healthcare sector, catering to the needs of individuals with diabetes. Short-acting insulin, also known as regular or fast-acting insulin, plays a pivotal role in managing blood glucose levels, particularly during mealtime. This market revolves around the production, distribution, and utilization of short-acting insulin products, which are indispensable for people with diabetes who require rapid and efficient insulin action. One of the primary factors driving the Short-Acting Insulin Market is the escalating prevalence of diabetes worldwide. As diabetes becomes more prevalent, especially with the rise in sedentary lifestyles and obesity, the demand for short-acting insulin has surged. This insulin variant is essential for controlling postprandial glucose levels, offering a rapid onset of action that aligns with mealtime requirements. The market responds to this growing demand by providing various formulations and delivery methods to ensure effective glucose management for individuals with diabetes. Technological advancements in insulin delivery systems and formulations represent another significant driver in the Short-Acting Insulin Market. Innovations such as insulin pens, pumps, and more refined insulin analogs enhance the convenience and precision of insulin administration. Patients benefit from these advancements as they contribute to improved adherence, reduced injection-related discomfort, and better overall glycemic control. Manufacturers compete to introduce novel technologies and formulations, fostering a competitive landscape that propels the market's evolution. Moreover, the market is influenced by an increased emphasis on personalized and patient-centric diabetes care. Tailoring insulin regimens to individual needs and lifestyles is a priority, leading to the development of more patient-friendly insulin delivery options. This includes not only the devices but also the insulin formulations themselves, with a focus on optimizing pharmacokinetics to mimic the physiological insulin response. The Short-Acting Insulin Market aligns with these trends, offering diverse options to suit the preferences and requirements of an increasingly diverse patient population.

Market dynamics are also shaped by the regulatory environment governing insulin products. Stringent regulatory standards ensure the safety, efficacy, and quality of short-acting insulin formulations. Market players invest in research and development to meet these standards while also exploring opportunities for regulatory approval in emerging markets. Regulatory compliance and adherence to quality standards are critical aspects that influence the market's competitive landscape and the level of trust among healthcare professionals and patients. Furthermore, the Short-Acting Insulin Market is characterized by robust research activities aimed at developing next-generation insulin products. This includes efforts to create ultra-rapid-acting insulins that more closely mimic the physiological insulin response, providing an even more precise and rapid onset of action. The pursuit of improved formulations and delivery systems reflects the commitment of market players to enhance the overall diabetes management experience for patients.

Key Market Drivers

Rising Diabetes Prevalence

The driving force behind the growth of the Short-Acting Insulin Market is the escalating prevalence of diabetes on a global scale. With diabetes reaching epidemic proportions, particularly type 2 diabetes linked to sedentary lifestyles and obesity, the demand for effective insulin management has surged. Short-acting insulin, known for its rapid onset and crucial role in controlling postprandial glucose levels, becomes indispensable for individuals requiring immediate and efficient insulin action during mealtime.

As more people are diagnosed with diabetes, the need for precise glucose control becomes paramount to prevent complications. Short-acting insulin addresses this need by offering a rapid response to elevated blood glucose levels after meals. The market aligns with this demand by providing various formulations and delivery methods to cater to diverse patient needs.

The rising prevalence of diabetes also amplifies the market's significance in preventing diabetes-related complications. Efficient glucose management, achieved through short-acting insulin, is crucial for preventing cardiovascular issues, kidney problems, and other diabetes-related complications. Consequently, the Short-Acting Insulin Market becomes an integral component of diabetes care, ensuring that individuals have access to advanced and effective insulin solutions to better manage their condition and improve their overall quality of life.

Personalized Diabetes Care

The Short-Acting Insulin Market is experiencing a transformative shift driven by the increasing emphasis on personalized diabetes care. As healthcare moves towards a more patient-centric approach, tailoring diabetes management strategies to individual needs becomes paramount, and short-acting insulin plays a pivotal role in this paradigm.

Personalized diabetes care recognizes the unique characteristics of each patient, including lifestyle, dietary habits, and insulin sensitivity. Short-acting insulin formulations and delivery methods are diversified to accommodate these individual factors, ensuring a tailored and precise approach to glycemic control. This customization not only enhances treatment efficacy but also improves patient adherence and satisfaction. Advanced insulin delivery systems, such as insulin pens and pumps, provide patients with options that align with their preferences and lifestyle. These technologies contribute to a more convenient and comfortable insulin administration experience, fostering better adherence to treatment plans. Additionally, the development of novel insulin analogs with specific pharmacokinetic profiles allows healthcare providers to fine-tune insulin regimens based on individual patient needs, optimizing glycemic control.

The shift towards personalized diabetes care represents a paradigmatic evolution in diabetes management. The Short-Acting Insulin Market, by offering a diverse range of options that can be tailored to individual requirements, stands at the forefront of this transformation, ensuring that patients receive not only effective but also personalized solutions for their diabetes treatment. This trend is likely to shape the future landscape of diabetes care, emphasizing precision and patient-centric approaches within the Short-Acting Insulin Market.


Download Free Sample Report

Key Market Challenges

Rising Costs

The Short-Acting Insulin Market faces a significant challenge in the form of rising costs associated with production and research. The complexity of insulin manufacturing processes, coupled with the need for continual research and development for innovative formulations and delivery systems, contributes to increased production expenses. These rising costs impact the affordability of short-acting insulin, potentially limiting access for patients. As insulin is a life-sustaining medication for those with diabetes, addressing the challenge of escalating costs becomes crucial to ensure widespread availability and affordability, ultimately promoting better glycemic control and overall diabetes management.

Access Disparities

Access disparities pose a substantial challenge in the Short-Acting Insulin Market, contributing to unequal global health outcomes. Limited access to affordable insulin in certain regions creates significant disparities in diabetes management. Economic factors, healthcare infrastructure variations, and regulatory hurdles contribute to these disparities. The high costs associated with insulin production and distribution further exacerbate the accessibility issue, preventing many individuals from obtaining essential short-acting insulin. Addressing access challenges is crucial to ensure that all individuals with diabetes, regardless of geographic location or socioeconomic status, can access and afford the life-saving medication needed for effective glycemic control and overall well-being.

Adherence Issues

Adherence issues present a significant challenge for the Short-Acting Insulin Market, impacting the effectiveness of diabetes management. Patient adherence to prescribed insulin regimens, including timing and dosage, is crucial for achieving optimal glycemic control. Factors such as fear of injections, inconvenience, or lack of understanding can contribute to non-adherence. This challenge may lead to suboptimal blood glucose control, increasing the risk of complications. Strategies addressing patient education, personalized treatment plans, and the development of more user-friendly delivery systems are essential to overcome adherence issues, ensuring that individuals with diabetes can effectively incorporate short-acting insulin into their daily routines.

Technological Gaps

Technological gaps pose a challenge for the Short-Acting Insulin Market, impacting the widespread adoption of advanced insulin delivery systems. While innovations like insulin pumps and pens enhance convenience and precision, accessibility remains an issue in certain regions. Limited technological infrastructure and awareness hinder the adoption of these advancements, leading to disparities in diabetes care. Bridging technological gaps requires efforts to improve healthcare infrastructure, educate healthcare providers and patients, and ensure affordability of advanced insulin delivery technologies. Overcoming these challenges is crucial to ensure that individuals globally can benefit from the latest technological advancements in short-acting insulin therapy, optimizing diabetes management.

Key Market Trends

Advanced Delivery Systems

Advanced delivery systems represent a prominent trend in the Short-Acting Insulin Market, reflecting a shift towards enhanced patient experience and improved glycemic control. Innovations such as insulin pens, pumps, and smart devices are gaining traction, offering convenient and precise administration. These technologies provide more flexibility, reduce injection-related discomfort, and improve overall adherence to insulin regimens. The trend emphasizes a patient-centric approach, focusing on user-friendly solutions that align with individual preferences and lifestyles. As the market continues to prioritize technological advancements, the integration of more sophisticated delivery systems is expected to play a pivotal role in shaping the future landscape of short-acting insulin therapy.

Biosimilar Market Expansion

The expansion of the biosimilar market is a notable trend in the Short-Acting Insulin Market, offering increased options for individuals with diabetes. Biosimilar short-acting insulin products, which mimic the properties of existing insulin formulations, contribute to market competitiveness and affordability. This trend fosters a more competitive landscape, potentially lowering overall insulin costs and enhancing accessibility. As more biosimilars receive regulatory approval and enter the market, the trend supports the goal of providing diverse and cost-effective insulin options. The biosimilar market expansion aligns with efforts to address the rising costs and access disparities associated with short-acting insulin, making diabetes management more sustainable for a broader population.

Digital Health Integration

Digital health integration is a prominent trend shaping the Short-Acting Insulin Market, bringing technology into the forefront of diabetes management. The incorporation of digital health tools, such as smartphone apps, continuous glucose monitoring (CGM) systems, and smart insulin pens, enhances the overall patient experience. These technologies provide real-time data, personalized insights, and convenient ways to monitor and administer short-acting insulin. The trend fosters a more connected and proactive approach to diabetes care, empowering individuals to make informed decisions. As the Short-Acting Insulin Market embraces digital solutions, the synergy between technology and insulin therapy is poised to revolutionize diabetes management for improved outcomes.

Continuous Glucose Monitoring Collaboration

The trend of collaboration with continuous glucose monitoring (CGM) systems is reshaping the Short-Acting Insulin Market. Integration with CGM technologies allows for real-time glucose monitoring, enabling more precise insulin dosing decisions. This collaborative trend enhances the synergy between short-acting insulin administration and glucose control, optimizing glycemic management. Patients benefit from a more streamlined and personalized approach, as CGM data informs insulin dosing adjustments in response to fluctuating glucose levels. The trend reflects a commitment to comprehensive diabetes care, emphasizing the importance of combining advanced insulin therapies with continuous monitoring solutions for more effective and patient-centric management of diabetes.

Segmental Insights

Drugs Insights

Based on the Drugs, Apidra, a brand of short-acting insulin (insulin glulisine), has established dominance in the market due to its rapid onset and shorter duration of action, making it an effective option for controlling postprandial glucose levels. Its quick response aligns with mealtime requirements, providing flexibility and precision in insulin dosing. Apidra's formulation reduces the risk of hypoglycemia and offers a more convenient treatment option for individuals with diabetes. With a proven track record and widespread acceptance, Apidra has become a preferred choice for healthcare providers, contributing to its dominance in the Short-Acting Insulin Market.

Application Insights

Type 1 diabetes dominance in the Short-Acting Insulin Market is rooted in the essential role short-acting insulin plays in managing this autoimmune condition. Individuals with type 1 diabetes lack natural insulin production, requiring external insulin to regulate glucose levels. Short-acting insulin, with its rapid onset, is crucial for addressing immediate postprandial glucose spikes. The precision in timing and dosage aligns with the dynamic insulin needs in type 1 diabetes, providing effective control. The prevalence of type 1 diabetes globally sustains the demand for short-acting insulin, solidifying its dominance in the market as a foundational component of type 1 diabetes management.


Download Free Sample Report

Regional Insights

North America's dominance in the Short-Acting Insulin Market is attributed to several factors. The region exhibits a high prevalence of diabetes, creating a substantial patient pool requiring insulin therapy. Robust healthcare infrastructure, advanced research facilities, and a well-established regulatory framework contribute to the development and adoption of innovative short-acting insulin formulations and delivery systems. Additionally, favorable reimbursement policies and a high level of awareness among healthcare professionals and patients enhance the market's growth. The presence of major pharmaceutical companies focusing on diabetes management further cements North America's position as a dominant player in the Short-Acting Insulin Market.

Recent Developments

  • In December 2023, USV Pharmaceuticals, in collaboration with the biotechnology firm Biogenomics, launched INSUQUICK, India's pioneering biosimilar of Insulin Aspart, with the objective of improving accessibility to diabetes care. INSUQUICK is a domestically manufactured product aligned with the "Make in India" initiative. It is meticulously crafted and produced utilizing indigenous technology and has undergone rigorous clinical trials to ensure compliance with international quality standards.

Key Market Players

  • Novo Nordisk AS
  • Sanofi SA
  • Eli Lilly & Co
  • Biocon Ltd
  • Wockhardt Ltd
  • Boehringer Ingelheim International GmbH
  • Julphar Pharma Inc
  • United Laboratories International Holdings Limited
  • Tonghua Dongbao Pharmaceutical Co. Ltd.

By Drugs

By Application

By Region
  • Apidra
  • Novolog
  • Humalog
  • Novolin
  • Others
  • Type 1 Diabetes
  • Type 2 Diabetes
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Short-Acting Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Short-Acting Insulin Market, By Drugs:

o   Apidra

o   Novolog

o   Humalog

o   Novolin

o   Others

  • Short-Acting Insulin Market, By Application:

o   Type 1 Diabetes

o   Type 2 Diabetes

  • Short-Acting Insulin Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Short-Acting Insulin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]               

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Global Short-Acting Insulin Market Outlook

4.1.  Market Size & Forecast

4.1.1.     By Value

4.2.  Market Share & Forecast

4.2.1.     By Drugs (Apidra, Novolog, Humalog, Novolin, Others)

4.2.2.     By Application (Type 1 Diabetes, Type 2 Diabetes)

4.2.3.     By Region

4.2.4.     By Company (2023)

4.3.  Market Map

4.3.1.     By Drugs

4.3.2.     By Application

4.3.3.     By Region

5.    Asia Pacific Short-Acting Insulin Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Drugs

5.2.2.     By Application

5.2.3.     By Country

5.3.  Asia Pacific: Country Analysis

5.3.1.     China Short-Acting Insulin Market Outlook

5.3.1.1.         Market Size & Forecast

5.3.1.1.1.             By Value

5.3.1.2.         Market Share & Forecast

5.3.1.2.1.             By Drugs

5.3.1.2.2.             By Application

5.3.2.     India Short-Acting Insulin Market Outlook

5.3.2.1.         Market Size & Forecast

5.3.2.1.1.             By Value

5.3.2.2.         Market Share & Forecast

5.3.2.2.1.             By Drugs

5.3.2.2.2.             By Application

5.3.3.     Australia Short-Acting Insulin Market Outlook

5.3.3.1.         Market Size & Forecast

5.3.3.1.1.             By Value

5.3.3.2.         Market Share & Forecast

5.3.3.2.1.             By Drugs

5.3.3.2.2.             By Application

5.3.4.     Japan Short-Acting Insulin Market Outlook

5.3.4.1.         Market Size & Forecast

5.3.4.1.1.             By Value

5.3.4.2.         Market Share & Forecast

5.3.4.2.1.             By Drugs

5.3.4.2.2.             By Application

5.3.5.     South Korea Short-Acting Insulin Market Outlook

5.3.5.1.         Market Size & Forecast

5.3.5.1.1.             By Value

5.3.5.2.         Market Share & Forecast

5.3.5.2.1.             By Drugs

5.3.5.2.2.             By Application

6.    Europe Short-Acting Insulin Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drugs

6.2.2.     By Application

6.2.3.     By Country

6.3.  Europe: Country Analysis

6.3.1.     France Short-Acting Insulin Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Drugs

6.3.1.2.2.             By Application

6.3.2.     Germany Short-Acting Insulin Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Drugs

6.3.2.2.2.             By Application

6.3.3.     Spain Short-Acting Insulin Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Drugs

6.3.3.2.2.             By Application

6.3.4.     Italy Short-Acting Insulin Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Drugs

6.3.4.2.2.             By Application

6.3.5.     United Kingdom Short-Acting Insulin Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Drugs

6.3.5.2.2.             By Application

7.    North America Short-Acting Insulin Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drugs

7.2.2.     By Application

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Short-Acting Insulin Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drugs

7.3.1.2.2.             By Application

7.3.2.     Mexico Short-Acting Insulin Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drugs

7.3.2.2.2.             By Application

7.3.3.     Canada Short-Acting Insulin Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drugs

7.3.3.2.2.             By Application

8.    South America Short-Acting Insulin Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drugs

8.2.2.     By Application

8.2.3.     By Country

8.3.  South America: Country Analysis

8.3.1.     Brazil Short-Acting Insulin Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drugs

8.3.1.2.2.             By Application

8.3.2.     Argentina Short-Acting Insulin Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drugs

8.3.2.2.2.             By Application

8.3.3.     Colombia Short-Acting Insulin Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drugs

8.3.3.2.2.             By Application

9.    Middle East and Africa Short-Acting Insulin Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drugs

9.2.2.     By Application

9.2.3.     By Country

9.3.  MEA: Country Analysis

9.3.1.     South Africa Short-Acting Insulin Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drugs

9.3.1.2.2.             By Application

9.3.2.     Saudi Arabia Short-Acting Insulin Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drugs

9.3.2.2.2.             By Application

9.3.3.     UAE Short-Acting Insulin Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drugs

9.3.3.2.2.             By Application

10.  Market Trends & Developments

10.1.  Drivers

10.2.  Challenges

11.  Market Trends & Developments

11.1.    Recent Developments

11.2.    Product Launches

11.3.    Mergers & Acquisitions

12.  Global Short-Acting Insulin Market: SWOT Analysis

13.  Porter’s Five Forces Analysis

13.1.    Competition in the Industry

13.2.    Potential of New Entrants

13.3.    Power of Suppliers

13.4.    Power of Customers

13.5.    Threat of Substitute Product

14.  Competitive Landscape

14.1.          Novo Nordisk AS

14.1.1.1.      Business Overview

14.1.1.2.      Company Snapshot

14.1.1.3.      Product & Services

14.1.1.5.      Financials (In case of listed)

14.1.1.6.      Recent Developments

14.1.1.7.      SWOT Analysis

14.2.    Sanofi SA

14.3.    Eli Lilly & Co

14.4.    Biocon Ltd

14.5.    Wockhardt Ltd

14.6.    Boehringer Ingelheim International GmbH

14.7.    Julphar Pharma Inc

14.8.    United Laboratories International Holdings Limited

14.9.    Tonghua Dongbao Pharmaceutical Co. Ltd.

15.  Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Short-Acting Insulin Market was estimated to be USD 6.75 Billion in 2023.

down-arrow

Short-acting insulin is a type of insulin with a rapid onset and a relatively short duration of action. It is commonly used to manage postprandial glucose levels in individuals with diabetes.

down-arrow

Novo Nordisk AS, Sanofi SA, Eli Lilly & Co, Biocon Ltd, Wockhardt Ltd, Boehringer Ingelheim International GmbH, Julphar Pharma Inc, United Laboratories International Holdings Limited, Tonghua Dongbao Pharmaceutical Co. Ltd. were the top players operating in the Global Short-Acting Insulin Market in 2023.

down-arrow

The Global Short-Acting Insulin Market is primarily driven by the escalating prevalence of diabetes, technological advancements in insulin delivery systems, a growing emphasis on personalized diabetes care, stringent regulatory compliance, and ongoing research for next-generation insulins, fostering market advancements and growth.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Short-Acting Insulin Market to Grow with a CAGR of 4.05% through 2029.

Apr, 2024

Rising Diabetes Prevalence and Personalized Diabetes Care are factors driving the Global Short-Acting Insulin Market in the forecast period 2025-2029.

Why Choose Us